Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018)

Maraka S.; Groves M. D.; Mammoser A. G.

首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018)

【24h】

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018)

机译：第1阶段进入替替莫替莫替莫替莫蛋白，Mefrooquine和二甲双胍的第2阶段阶段研究，作为新诊断的胶质母细胞瘤的生物辅助治疗（Vol 125，PG 424,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Cancer: A Journal of the American Cancer Society》 |2019年第8期|共1页
作者
Maraka S.; Groves M. D.; Mammoser A. G.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018) [J] . Maraka S., Groves M. D., Mammoser A. G. Cancer: A Journal of the American Cancer Society . 2019,第8期

机译：第1阶段进入替替莫替莫替莫替莫蛋白，Mefrooquine和二甲双胍的第2阶段阶段研究，作为新诊断的胶质母细胞瘤的生物辅助治疗（Vol 125，PG 424,2018）
2. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma [J] . Mark R. Gilbert, Javier Gonzalez, Kathy Hunter, Neuro-Oncology . 2010,第11期

机译：单独进行剂量密集的替莫唑胺和沙利度胺，异维A酸和/或塞来昔布联合化疗作为放疗后辅助治疗新发胶质母细胞瘤的I期析因设计研究
3. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment (vol 100, pg 1195, 2018) [J] . Kong X-T, Nguyen N. T., Choi Y. J., International Journal of Radiation Oncology, Biology, Physics . 2019,第5期

机译：Bortezomib的第2阶段研究结合替代唑吡喃胺和区域放射治疗对新诊断的胶质母细胞瘤患者的前期治疗多形状：安全性和疗效评估（Vol 100，PG 1195,2018）
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide isotretinoin and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma [O] . Mark R. Gilbert, Javier Gonzalez, Kathy Hunter, 2010

机译：单独进行剂量密集的替莫唑胺联合沙利度胺异维A酸和/或塞来昔布联合化疗作为放疗后辅助治疗新发胶质母细胞瘤的I期析因设计研究
6. Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma [O] . Stefania Maraka, Morris D. Groves, Aaron G. Mammoser, 2018

机译：第1阶段进入替代灭菌菌，Mefrooquine和二甲双胍作为新诊断的胶质母细胞瘤的药物辅助治疗

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018)

著录项

相似文献

相关主题

期刊订阅